Laidlaw analyst Yale Jen downgraded Soleno Therapeutics (SLNO) to Hold from Buy without a price target after Neurocrine (NBIX) announced the acquisition of Soleno for $2.9B or $53 per share in cash. The firm views the dal as a positive due to the premium to the recent Soleno share price.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics rises 32.2%
- Midday Fly By: Neurocrine to acquire Soleno, Oracle hires new CFO
- Morning Movers: Soleno pops, Neurocrine dips after acquisition agreement
- Soleno Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Soleno Therapeutics to Be Acquired by Neurocrine Biosciences